Published: 3 March 2022

Publications

Quarterly summary of recent safety communications

Published 3 March 2022
Prescriber Update 43(1): 11
March 2022

The table below is a summary of recent safety communications to health care professionals and consumers, published on the Medsafe website.

Date Communication Topic
  COVID-19 Adverse events following immunisation with COVID-19 vaccines
20/02/22 Monitoring Buccaline tablets: review of the benefits and risks under section 36 of the Medicines Act 1981
19/02/22 Monitoring Update – Pregabalin and the possible risk of bullous dermatitis and exfoliating skin reactions
16/02/22 Consultation Proposed warning and advisory statement relating to the harm of opioid abuse, misuse, and dependence (closes 4 April 2022)
15/02/22 Monitoring Update – Dihydrocodeine: review of risks and benefits
31/01/22 Dear Healthcare Professional Letter Ronapreve (casirivimab and imdevimab): reduced neutralisation activity of the antibody combination against the full-length S protein of the Omicron variant of COVID-19 (PDF, 217 KB, 3 pages)
24/12/21 Dear Healthcare Professional Letter Important information about Ronapreve (casirivimab and imdevimab) supplied in New Zealand (PDF, 362 KB, 3 pages)
22/12/21 Dear Healthcare Professional Letter Supply of new formulation of Comirnaty (COVID-19 Vaccine) in New Zealand (PDF, 365 KB, 10 pages)
22/12/21 Alert Medsafe is issuing a warning not to use Goree Beauty Cream with Lycopene, Goree Day and Night Beauty Cream Oil Free, and Golden Pearl Beauty Cream - statement under section 98 of the Medicines Act 1981
20/12/21 Alert Reminder: Comirnaty vaccination (Pfizer COVID-19 vaccine) can cause myocarditis and pericarditis
06/12/21 Dear Healthcare Professional Letter Labelling exemption - Cuprior (trientine) 150 mg film-coated tablet (PDF, 265 KB, 2 pages)
03/12/21 Dear Healthcare Professional Letter Alecensa (alectinib) - Warnings and precautions and specific dose modification guidance for management of haemolytic anaemia (PDF, 243 KB, 2 pages)
22/11/21 Dear Healthcare Professional Letter Distinguishing between Thrombosis and Thrombosis with Thrombocytopenia (TTS) following COVID-19 (AstraZeneca and Janssen) vaccinations (PDF, 291 KB, 3 pages)
18/11/21 Dear Healthcare Professional Letter Update on tenecteplase supply shortage (PDF, 2 pages, 373 KB)
17/11/21 Dear Healthcare Professional Letter Supply of COVID-19 Vaccine AstraZeneca in New Zealand (PDF, 3 pages, 215 KB)
Hide menus
Show menus
0 1 2 4 5 6 7 9 [ /